Viyash Scientific Limited

NSE: VIYASH · Pharmaceuticals · sector

₹207.87NSE close 2026-10-26

Key numbers

Market cap₹9,081 cr

Price₹207.87

52w high / low₹298 / ₹178

P/E49.6xSector median 27.9x

P/B3.1xSector median 2.9x

Book value₹66.6

Dividend yield0.05%Sector median 0.48%

ROE9.5%Sector median 11.7%

ROCE11.8%Sector median 12.3%

OPM17.5%Sector median 14.0%

Debt / equity0.15xSector median 0.16x

EV/EBITDA16.8xSector median 18.6x

Interest cover6.9x

Current ratio2.38x

Sales growth 3y+34.0%Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG0.12x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹270 cr vs borrowings ₹436 cr (FY26): borrowings are higher by ₹166 cr.
Operating profit covered interest 6.9x in the last 12 months.
No promoter shares are pledged.
Promoter holding fell by 3.09 percentage points in a year, to 49.24% (2026-09-30).
Operating cash flow was below net profit in 1 of the last 5 years (FY22).
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 24% of net profit in the last 12 months.
Debtor days went from 89 (FY24) to 112 (FY26).
Dividend paid in 1 of the last 5 financial years.
Price ₹207.87 on 2026-10-26: -30.2% from the 52-week high, +16.7% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹288.20 · low ₹132.09

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	369	391	402	441	424	858	920	946
EBITDA	35	34	46	51	54	134	184	178
OPM %	9.4%	8.7%	11.4%	11.5%	12.7%	15.7%	20.0%	18.8%
Other income	5	6	2	4	2	14	16	8
Net profit	6	3	9	14	15	38	52	66
EPS (₹)	0.10	0.14	0.37	0.57	0.59	0.89	1.20	1.51
Revenue YoY					+15.0%	+119.6%	+129.0%	+114.4%
Profit YoY					+132.5%	+1,017.4%	+459.1%	+360.3%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	1,413	1,421	1,370	1,551	3,420	3,149
EBITDA	109	-53	44	157	608	551
Net profit	41	-121	-36	22	177	171
EPS (₹)	1.67	-4.88	-1.44	0.88	4.09	4.19
Revenue growth		+0.6%	-3.6%	+13.3%	+120.5%	+96.5%
Profit growth		-393.7%	–	–	+710.2%	+412.3%
Dividend / share (₹)	0.50	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+34.0%	+20.2%	+96.5%
Net profit	–	+13.2%	+412.3%
EPS	–	+1.1%	–
Share price	–	– (2y)	–

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	699	657	704	2,911
Borrowings	–	398	451	446	436
Cash & equivalents	–	42	72	69	270
Total assets	–	1,529	1,540	1,602	4,628
Fixed assets	–	301	249	232	1,138
Capital work in progress	–	51	11	15	69
Investments	–	0	1	0	0
Receivables	–	341	336	363	1,045
Inventory	–	346	346	385	803
Payables	–	244	260	257	597

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	31	17	31	83	323
Cash from investing	-94	-65	-6	-25	-84
Cash from financing	67	32	-1	-61	-123
Capex	32	86	31	39	135
Free cash flow	-2	-69	-0	44	188

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	-17.3%	-5.5%	3.1%	6.1%
ROCE %	–	-9.3%	-0.6%	9.1%	12.5%
Debtor days	–	88	89	85	112
Inventory days	–	152	166	173	188
Payable days	–	107	125	115	140
Cash conversion cycle (days)	–	133	130	143	160
Working capital days	–	65	49	87	140

Shareholding

Holder	% (2026-09-30)
Promoters	49.24%
FIIs	2.60%
DIIs	8.30%
of which Mutual funds	7.13%
of which Insurance	0.00%
Government	0.00%
Public (non-institutions)	39.76%

Quarter	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	52.61%	52.61%	52.33%	61.43%	61.41%	61.31%	61.31%	49.24%

Promoter group	%
CA Hull Investments	25.03%
CA Harbor Investments	24.21%

Public holders above 1%	%
Kotak Contra Fund	4.05%
Haribabu Bodepudi	2.74%
Kalidindi Srihari Raju	2.23%
Bandhan Large & MID CAP Fund	1.97%
Narasimha Reddy Duthala	1.16%

1,42,732 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
VIYASH	₹9,081 cr	49.6x	3.1x	9.5%	11.8%	17.5%	+34.0%	0.05%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2021-09-08	Dividend	Dividend - Rs 0.50 Per Share
2019-08-21	Dividend	Annual General Meeting/Dividend - Rs 0.20 Per Share
2018-04-06	Restructuring	Scheme Of Arrangement
2017-11-20	Dividend	Interim Dividend - Re 0.20 Per Share
2016-09-15	Other	Annual General Meeting

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	VIYASH
BSE code	512529
ISIN	INE807F01027
Face value	₹2.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.